Navigation Links
BSP Raises $2.6 Million Dollars From Private Investors

TEL AVIV, Israel, June 17 /PRNewswire-FirstCall/ -- BSP Ltd., ( an Israeli company which develops and markets systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease, announced that they successfully raised $2.6 million in a private funding round, that included existing shareholders in the company as well as new investors.

BSP developed the HyperQ(TM), a cutting-edge technology that offers highly reliable, low-cost and risk free cardiac monitoring for broad populations and allows, for the first time, effective and accurate testing for Ischemic Heart Disease - the No. 1 killer in the world.

Thousands of patients in Israel, Europe and the US have already been examined by HyperQ(TM) Stress Systems in controlled clinical studies, pilot programs and routine testing. The results have demonstrated the system's high efficiency and unmatched accuracy in the diagnosis of IHD. The HyperQ(TM) system received FDA clearance (510K), as well as the European CE marking.

The company has entered the clinical and commercial phase, during which the HyperQ(TM) Stress System will be integrated in inpatient and outpatient hospital settings, private doctor offices and major research centers.

Further applications on the company's scope; include bedside monitors for ischemic events; devices for cardiac home-care and telemedicine; and the implementation of the HyperQ(TM) technology in implantable cardiac devices.

"The completion of this round reflects our investors' ongoing confidence in our ability to meet our commercial and clinical milestones. This round will enable us to step-up the marketing and business development efforts in the US, and accelerate development of BSP's next application - the HyperQ bedside monitor," said Dr. Amir Beker, CEO of BSP.

Dr. Beker added, "The HyperQ(TM) technology is a revolutionary non-invasive solution to today's most fatal pathology. It improves the standard of care for cardiac patients, decreases the risk of further, often invasive, tests, and addresses the dire needs of private and national healthcare systems to balance the immense costs of cardiac diagnosis and monitoring."

About BSP

BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP was founded in 2000 by Dr. Amir Beker and Mr. Ariel Landau and has completed a successful IPO in mid-2006 and its shares are traded on the Tel Aviv Stock Exchange. Visit:

Contact: Dr. Amir Beker, CEO or Dr. Neri Malka, Head of Clinical Marketing: +972-3-6474840

SOURCE BSP - Biological Signal Processing Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
2. Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
3. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
4. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
5. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
6. Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%.
7. Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance
8. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
9. Stemline Therapeutics Raises $12.5 Million
10. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
11. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
Post Your Comments:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):